Related Experiment Video

Updated: Sep 25, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

292

FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs

Jae-Sook Ahn1,2, Hyeoung-Joon Kim1,2

  • 1Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University, Gwangju, Korea.

Blood Research
|April 28, 2022
PubMed

Insights

FMS-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML). This review details FLT3 inhibitors, including midostaurin and gilteritinib, for managing FLT3-mutated AML.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent genetic alterations in acute myeloid leukemia (AML), found in about 30% of newly diagnosed cases.
  • These mutations are particularly common in AML patients with normal karyotypes.

Purpose of the Study:

  • To review clinically available FMS-like tyrosine kinase 3 (FLT3) inhibitors for treating acute myeloid leukemia (AML) with FLT3 mutations.
  • To summarize current and emerging treatment strategies for FLT3-mutated AML.

Main Methods:

  • Literature review of clinical trials and practice guidelines.
  • Analysis of data on FLT3 inhibitors in AML management.

Main Results:

  • Midostaurin is part of the standard induction chemotherapy (7+3) for newly diagnosed FLT3-mutated AML.
  • Gilteritinib demonstrates superior efficacy compared to salvage chemotherapy in relapsed or refractory FLT3-mutated AML.

Conclusions:

  • FLT3 inhibitors represent a significant advancement in the treatment of FLT3-mutated AML.
  • Ongoing research is expanding therapeutic options for patients with FLT3-mutated AML, considering disease status and patient factors.
Keywords:
Acute myeloid leukemiaGilteritinibMidostaurinTyrosine kinase inhibitor

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K